Page 2157 - Williams Hematology ( PDFDrive )

2132 Part XII: Hemostasis and Thrombosis <CN>: <CT> PB

103. Reijnen MJ, Sladek FM, Bertina RM, Reitsma PH: Disruption of a binding site for 114. Wilde J, Teixeira P, Bramhall SR, et al: Liver transplantation in haemophilia. Br J Haematol
hepatocyte nuclear factor 4 results in hemophilia B Leyden. Proc Natl Acad Sci U S A 117:952, 2002.
89:6300, 1992. 115. High KA, Nathwani A, Spencer T, Lillicrap D: Current status of haemophilia gene ther-
104. Lusher JM, McMillan CW: Severe factor VIII and factor IX deficiency in females. Am J apy. Haemophilia 20:43, 2014.
Med 65:637, 1978. 116. Monahan PE, Gui T: Gene therapy for hemophilia: Advancing beyond the first clinical
105. Goodeve AC: Laboratory methods for the genetic diagnosis of bleeding disorders. Clin success. Curr Opin Hematol 20:410, 2013.
Lab Haematol 20:3, 1998. 117. Chuah MK, Evens H, VandenDriessche T: Gene therapy for hemophilia. J Thromb Haemost
106. White GC, Bebe A, Nielsen B: Recombinant factor IX. Thromb Haemost 78:261, 1997. 11:99, 2013.
107. Escobar MA: Advances in the treatment of inherited coagulation disorders. Haemophilia 118. Nathwani AC, Reiss UM, Tuddenham EG, at al: Long-term safety and efficacy of factor
19:648, 2013. IX gene therapy in hemophilia B. N Engl J Med 371:1994, 2014.
108. Wolberg AS, Stafford DW, Erie DA: Human factor IX binds to specific sites on the col- 119. Ma A, Roberts HR, Escobar MA, editors: Haemophilia and Haemostasis: A Case-Based
lagenous domain of collagen IV. J Biol Chem 272:16717, 1997. Approach to Management, 2nd ed. Blackwell, Oxford, 2012.
109. Kim HC, McMillan CW, White GC, et al: Purified factor IX using monoclonal 120. Girolami A, Ruzzon E, Fabris F, et al: Myocardial infarction and other arterial occlu-
immunoaffinity technique: Clinical trials in hemophilia B and comparison to proth- sions in hemophilia A patients. A cardiological evaluation of all 42 cases reported in the
rombin complex concentrates. Blood 79:568, 1992. literature. Acta Haemotol 116:120, 2006.
110. Puetz J, Soucie JM, Kempton CL, et al: Prevalent inhibitors in haemophilia B subjects 121. Kulkarni R, Soucie JM, Evatt BL: Prevalence and risk factors for heart disease among
enrolled in the Universal Data Collection database. Haemophilia 20:25, 2014. males with hemophilia. Am J Hematol 79:36, 2005.
111. High KA: Factor IX: Molecular structure, epitopes, and mutations associated with 122. Mannucci PM, Schutgens RE, Santagostino E, et al: How I treat age-related morbidities
inhibitor formation, in Inhibitors to Coagulation Factors, edited by LM Aledort, LW in elderly persons with hemophilia. Blood 114:5256, 2009.
Hoyer, JM Lusher, HM Reisner, CG White, p 79. Plenum, New York, 1995. 123. Tuinenburg A, Damen SAj, Ypma PF, et al: Cardiac catheterization and intervention
112. Warrier I, Ewenstein BM, Koerper MA, et al: Factor IX inhibitors and anaphylaxis in in haemophilia patients: Prospective evaluation of the 2009 institutional guideline.
hemophilia B. J Pediatr Hematol Oncol 19:23, 1997. Haemophilia 19:370, 2013.
113. Bontempo FA, Lewis JH, Gorenc TJ, et al: Liver transplantation in hemophilia A. Blood
69:1721, 1987.

Kaushansky_chapter 123_p2113-2132.indd 2132 9/21/15 4:36 PM